that was also my conclusion after reading the May 2018 publication. I have always believed that Linda Liau was very accurate in giving data. I believe that ALL placebo patients had progression in November 2016.At that moment all placebo patients had the possibility to get dcvax-L and I think that was the reason for the FDA to lift the hold. And remember, it was also the period that the Company started to communicate about the first endpoint and the promise that no more patients would be recruited! IMO
How does your post inform your opinion on immediate unblinding? And I'm not sure how we can infer that 99% of placebo had progressed by Nov '16. Are you concluding that PFS endpoint is likely met? Do you think there is no need to extend the trial any further to demonstrate OS treatment advantage and long tail?
Flipper, very interesting.... But, if the trial was still blinded, how would LL know how many placebos had not progressed or know how many patients had declined to use dcvax? She would know the total for these two groups was 14% of the ITT, but how would she know the ratio between these two groups?